ReviewCureus2026
Clear Cell Hidradenoma: A Review of Reported Cases.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell hidradenoma (CCH) is an extremely rare benign adnexal skin tumor originating from eccrine sweat glands. The purpose of this systematic review is to analyze and demonstrate trends in the location, occurrence, and presentation of CCH as well as its ability to present in advanced disease states. This study identified 460 case reports published from 1979 through 2022 through PubMed searches. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were tightly adhered to. The search keywords were "acrospiroma" and "clear cell hidradenoma." Investigators reviewed the articles and extracted the following information: demographics; medical history and medications; anatomic location and characteristic of the CCH; malignancy; and CCH progression timeline. Of the 460 cases reported, 228 reports with 241 cases of CCH were included in the final analysis. The average age is 54.7 (±21.1) years old, and 54.36% are females. Thirty-five CCH cases were reported to be malignant. The genitourinary system is the most common location for malignant CCH. No statistically significant difference in malignant transformation was observed between genders (p=0.24). Malignant CCH had a mean length 2 cm greater than nonmalignant CCH (p-value=0.023). Cases with reported malignant CCH had CCH for a mean of 2.75 years longer than nonmalignant CCH cases (p-value=0.048). CCH is a rare skin tumor commonly found in genitourinary, facial, and head areas. No significant gender difference was found when looking at malignant CCH. The length of the CCH and the time it grows could be indicators of malignant CCH. Careful histopathologic examination, biopsy, and surgical excision of the tumor are recommended, although there is a chance of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.